1ST Source Corp (SRCE) investors sentiment decreased to 0.8 in 2017 Q4. It’s down -0.33, from 1.13 in 2017Q3. The ratio has dropped, as 40 investment professionals opened new or increased positions, while 50 sold and reduced stakes in 1ST Source Corp. The investment professionals in our database now hold: 17.97 million shares, down from 18.16 million shares in 2017Q3. Also, the number of investment professionals holding 1ST Source Corp in top ten positions was flat from 1 to 1 for the same number . Sold All: 7 Reduced: 43 Increased: 26 New Position: 14.

Adams Express Company decreased Enanta Pharmaceuticals Inc. (ENTA) stake by 46% reported in 2017Q4 SEC filing. Adams Express Company sold 9,200 shares as Enanta Pharmaceuticals Inc. (ENTA)’s stock rose 40.76%. The Adams Express Company holds 10,800 shares with $634,000 value, down from 20,000 last quarter. Enanta Pharmaceuticals Inc. now has $1.81 billion valuation. The stock increased 2.40% or $2.22 during the last trading session, reaching $94.56. About 57,873 shares traded. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has risen 160.80% since April 29, 2017 and is uptrending. It has outperformed by 149.25% the S&P500.

Since January 1, 0001, it had 1 insider buy, and 1 sale for $441,072 activity.

The stock decreased 0.04% or $0.02 during the last trading session, reaching $52.82. About 29,054 shares traded. 1st Source Corporation (SRCE) has risen 10.80% since April 29, 2017 and is uptrending. It has underperformed by 0.75% the S&P500.

1st Source Corporation operates as the bank holding firm for 1st Source Bank that provides commercial and consumer banking services, trust and investment management services, and insurance to individual and business clients. The company has market cap of $1.37 billion. The Company’s consumer banking services include checking and savings accounts; certificates of deposit; individual retirement accounts; on-line and mobile banking products; automated teller machine services; consumer loans, real estate loans, and lines of credit; and financial planning, financial literacy, and other consultative services. It has a 20.32 P/E ratio. The firm also offers commercial, small business, agricultural, and real estate loans for general corporate purposes, including financing for industrial and commercial properties, equipment, inventories, accounts receivables, and acquisition financing; and commercial leasing, treasury management, and retirement planning services.

Analysts await Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to report earnings on May, 14. They expect $0.09 EPS, up 132.14% or $0.37 from last year’s $-0.28 per share. ENTA’s profit will be $1.72M for 262.67 P/E if the $0.09 EPS becomes a reality. After $0.78 actual EPS reported by Enanta Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -88.46% negative EPS growth.

Since March 19, 2018, it had 0 insider buys, and 2 sales for $1.14 million activity. MELLETT PAUL J also sold $778,331 worth of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) shares. Adda Nathalie sold $361,560 worth of stock.